Messenger RNA Based Vaccines and Their immunological effect on diseases


  • Osama Mohammed Hasan Dentistry College / Mustansiriyah University



Mrna, transform cell, immunity, vaccine


Because of its capabilities for fast development, potency, secure delivery, and promise for   cost effective manufacture, mRNA vaccines are a promising vaccination technique. Many recent research has suggested that mRNA vaccines could be effective intreating a wide range of tumor and viral disorders where standard vaccine techniques have failed to stimulate protective immune responses. The inefficient and unstable in vivo distribution of mRNA has limited their application. Direct electroporation of mRNA vaccines into dendritic cells induced the generation of protective antibodies capable of destroying infected or transformed cells and inducing polyclonal CD8+ and CD4+ that mediated Ag specific T cell responses. in this review mRNA vaccines in detail were examined, as well as future objectives and challenges in the prevention of infectious diseases


- Pardi N, Hogan M.J, Porter F.W, Weissman D. mRNA vaccines-a new era in vaccinology. Nat. Rev. Drug Discov. 2018; 17: 261–279.

- Plotkin, S.A. Vaccines: The fourth century. Clin. Vaccine Immunol. 2009; 16: 1709–1719.

- Wolff J.A, Malone R.W, Williams P, Chong W, Acsadi G, Jani A, Agnes F, Philip L. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465–1468.

- Cheng W. F. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 2001 ;75: 2368–2376.

- Thess, A. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 2015; 23 :1456–1464.

- Hobernik D, Bros M. DNA vaccines-how far from clinical use. Int J Mol Sci. 2018;19 :3605.

- Annkristin H, Stefan J, Peter Brossart. Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer. 2021; 20:52

- Pardi N, Muramatsu H, Weissman D, Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 2013 ;969: 29–42.

- Grudzien N. E. Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. Meth. Enzym. Ch. 2007;431: 203–227.

- Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5’- Triphosphate RNA is the ligand for RIG-I. Science. 2006; 314:994–7.

- Gallie D. R. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev.1991; 5: 2108–2116.

- Strzelecka D, Smietanski M, Sikorski PJ, Warminski M, Kowalska J, Jemielity J. Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression. RNA. 2020; 26:1815–37

- Leppek, K, Das R, Barna M. Functional 5ʹ UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat. Rev. Mol. Cell Biol.2018 ;19: 158–174.

- Mauro VP, Chappell SA. Considerations in the use of codon optimization for recombinant protein expression. In: Hacker DL, editor. Recombinant protein expression in mammalian cells. New York: Springer New York. 2018; 1850 :275–88

- Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann K.K, Schlee M, et al.50-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314: 994–997.

- Pardi N, Muramatsu H, Weissman D, Karikó K. In vitro transcription of long rna containing modified nucleosides. In: Rabinovich PM, editor. Synthetic messenger RNA and cell metabolism modulation. Totowa: Humana Press; 2013;969: 29–42.

- Pardi, N. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med.2018 ;215: 1571–1588.

- Thess A, Grund S, Mui B.L, Hope M.J, Baumhof P, Fotin-Mleczek M, Schlake T. Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol. Ther. 2015; 23: 1456–1464.

- Islam M.A, Reesor E.K.G, Xu Y, Zope H.R, Zetter B.R, Shi J. Biomaterials for mRNA delivery. Biomater. Sci. 2015; 109: 78–87.

- Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020; 65:14–20.

- Hoerr, I., Obst, R., Rammensee, H. G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 2000; 30:1–7.

- Scheel B, Teufel R, Probst J, Carralot J.P, Geginat J, Radsak M, Jaroslav D, Wagner H, Jung G, Rammensee H.G, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol. 2005; 35:1557–1566.

- Barroso da Silva F.L, Derreumaux P,Pasquali S. Protein-RNA complexation driven by the charge regulation mechanism. Biochem. Biophys. Res. Commun. 2018; 498: 264–273.

- Qiu P, Ziegelhoffer P, Sun J, Yang, N. S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther.1996 ;3: 262–268.

- Kranz L.M, Diken M, Haas H, Kreiter S, Loquai C, Reuter K.C, Meng M, Fritz D Vascotto F, Hefesha, H. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534:396–401.

- Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber ANR, A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol. 2011; 186:4213–22.

- Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23: 165-75.

- Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39: e142.

- McNamara M.A, Nair S.K, Holl E.K. RNA-Based Vaccines in Cancer Immunotherapy. J. Immunol. Res. 2015; 2015:1- 9.

- Kurts C, Robinson BWS, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol. 2010; 10:403–14.

- Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunologicaland clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res.2003; 63: 2127–2133.

- Chen N, Xia P, Li S, Zhang T, Wang TT, Zhu J. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life. 2017; 69:297–304.

- Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413:732–8.

- Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber ANR, A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol.